en · de · es · fr · pt
sr9009-notes.peptides5388.com › Guide › Background And Receptor Mechanism — Worked Examples

Background And Receptor Mechanism — Worked Examples

By Editorial Desk · published 2026-02-05 · last reviewed 2026-03-17 · Guide

circadian rhythm comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-03-17. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Analytical and Handling Considerations

Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.

SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.

For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic small moleculeStudied as a REV-ERB agonist
Molecular formulaC20H24ClN3O4SReported for the neutral compound
AppearanceOff-white to pale yellow solidTypical research-grade material
SolubilitySparingly soluble in waterSoluble in solvents such as DMSO
Common synonymsSR9009; StenabolicStenabolic is an informal alias

Analytical Detection and Regulatory Status

Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Related pages on this site

Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Mechanism and Preclinical Findings

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

Regulation, Testing, and Storage

SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.

Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.

Further detail

== Legacy == The Eunuch Culture Museum, located in the Shijingshan district of Beijing, is a museum dedicated to the history of eunuchs in China. It was established on the premises of the tomb of Tian Yi, a famous Ming eunuch who lived from 1534 to 1605. Items now on display mainly consist of articles left behind by Sun; such as his chair, walking stick, and a yellow jacket given to him by Puyi. His biography, The Last Eunuch of China, written by Chinese writer Jia Yinghua, was published in 1998 and translated into English in 2008. Lai Shi, China's Last Eunuch is a 1988 Hong Kong historical drama directed by Jacob Cheung which is loosely based on Sun Yaoting's life, taking inspiration from his biography.

==== Cell culture using droplet-based microfluidics ==== Droplet-based microfluidic systems provide an analytic platform that enables the isolation of single cells or groups of cells in droplets. This tool offers high-throughput for cell experiments since droplet-based microfluidic systems can generate thousands of samples (droplets) per second. Compared with cell culture in conventional microtiter plates, microdroplets from μL to pL volumes reduce the use of reagents and cells. Additionally, automated handling and continuous processing allow assays to be carried out more efficiently. The isolated environment in an encapsulated droplet helps analyze each individual cell population. High-throughput cell culture experiments, for example, testing the behavior of bacteria, finding rare cell types, directed evolution, and cell screening are suitable for using the droplet-based microfluidic techniques.

Large lamps may have a screw base or a bayonet base, with one or more contacts on the base. The shell may serve as an electrical contact or only as a mechanical support. Bayonet base lamps are frequently used in automotive lamps to resist loosening by vibration. Some tubular lamps have an electrical contact at either end. Miniature lamps may have a wedge base and wire contacts, and some automotive and special purpose lamps have screw terminals for connection to wires. Very small lamps may have the filament support wires extended through the base of the lamp for connections. A bi-pin base is often used for halogen or reflector lamps. In the late 19th century, manufacturers introduced a multitude of incompatible lamp bases. General Electric's "Mazda" standard base sizes were soon adopted across the US. Lamp bases may be secured to the bulb with a cement, or by mechanical crimping to indentations molded into the glass bulb. Lamps intended for use in optical systems have bases with alignment features so that the filament is positioned accurately within the optical system. A screw-base lamp may have a random orientation of the filament when the lamp is installed in the socket. Contacts in the lightbulb socket allow the electric current to pass through the base to the filament. The socket provides electrical connections and mechanical support, and allows changing the lamp when it burns out.

Sources: en.wikipedia.org

Background from the literature

The N-hydroxyphthalimide can be removed by shaking with sodium bicarbonate, but the N-hydroxysuccinimide approach shows greater reactivity and convenience, and is generally preferred. Esters of N-hydroxyphthalimide and activated sulfonic acids such as trifluoromethanesulfonic anhydride or p-toluenesulfonyl chloride are used as so-called photoacids, which split off protons during UV irradiation.

Post-SSRI sexual dysfunction (PSSD) is an iatrogenic condition in which sexual side effects persist after discontinuation of serotonin reuptake inhibiting antidepressants, including escitalopram. Characteristic symptoms include genital numbness, pleasureless or weak orgasm, loss of libido, and erectile dysfunction; non-sexual symptoms such as emotional blunting and cognitive impairment may also occur. The condition can arise after even brief exposure to a serotonin reuptake inhibitor and may persist indefinitely; there is currently no established treatment. The DSM-5 noted in 2013 that serotonin reuptake inhibitor-induced sexual dysfunction may persist after the agent is discontinued. A 2023 retrospective cohort study of over 12,000 males estimated the risk of irreversible sexual dysfunction at approximately 0.46% of patients treated with serotonergic antidepressants, including SSRIs, though the actual prevalence remains uncertain and the condition is likely underreported. A 2023 systematic review found that escitalopram was the single most frequently reported SSRI in PSSD case reports, followed by citalopram, paroxetine, sertraline, and fluoxetine. In 2019, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) recommended that product labels for all SSRIs and SNRIs, including escitalopram, be updated to state that sexual dysfunction may be long-lasting even after treatment is stopped. Health Canada followed with similar label updates in 2021.

Among the most famous were Milon of Croton, who won six wrestling events in six consecutive Olympics, along with seven events in the Pythian Games, nine events in the Nemean Games and ten events in the Isthmian Games and also Astylos of Croton, who won six running events in three consecutive Olympics. Through Alcmaeon of Croton (a philosopher and medical theorist) and Pythagoras (a mathematician and philosopher), who moved to Kroton in 530 BCE, the city became a center of philosophy, science and medicine. The Greeks of Sybaris created "Intellectual Property". The Sybarites founded at least 20 other cities, including Poseidonia (Paestum in Latin, on the Tyrrhenian coast of Lucania), Laüs (on the border with Lucania) and Scidrus (on the Lucanian coast in the Gulf of Taranto). Locri was renowned as the town where Zaleucus created the first Western Greek law, the "Locrian Code" and the birthplace of ancient epigrammist and poet Nossis. The Greek cities of Calabria came under pressure from the Lucanians who conquered the north of Calabria and pushed further south, taking over part of the interior, probably after they defeated the Thurians near Laus in 390 BCE. Decades later the Bruttii took advantage of the weakened Greek cites caused by wars between them and took over Hipponium, Terina and Thurii. The Bruttii helped the Lucanians fight Alexander of Epirus (334–32 BCE), who had come to the aid of Tarentum (in Apulia), which was also pressured by the Lucanians.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.

Is SR9009 a SARM?

No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.

What human data exist for SR9009?

Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.

How is SR9009 detected in laboratory samples?

Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.

Network